4 things to know about the new sunscreen ingredient the FDA approved

FDA approves bemotrizinol, a new chemical UV filter, for use in US sunscreens. The ingredient, already used in Europe and Asia, blocks UVA and UVB rays, offering broad-spectrum protection.

Dermatologists are hailing the approval as a significant development, citing bemotrizinol's ability to provide long-lasting protection against both types of UV rays. Dr. Heather Rogers, a dermatologist in Seattle and fellow of the American Academy of Dermatology, says the new ingredient "hits every box" for what dermatologists and consumers have been waiting for.

The approval comes after nearly three decades without a new chemical UV filter being approved for use in US sunscreens. The FDA's rigorous testing process, which classified sunscreens as over-the-counter drugs rather than cosmetics, contributed to the delay. European company DSM-Firmenich spent over $18 million and two decades to gain FDA approval for bemotrizinol.

Bemotrizinol's advantages over existing chemical sunscreen ingredients include its photostability, meaning it breaks down more slowly when exposed to sunlight. This offers better protection, especially for people who may not reapply sunscreen every two hours. In contrast, avobenzone, a common ingredient in US sunscreens, can break down rapidly and release molecules that lead to skin irritation.

The new ingredient has undergone extensive testing, including animal and human clinical trials, which showed no concerns about reproductive harm or skin irritation. Bemotrizinol's larger molecules also make it less likely to be absorbed by the skin and into the bloodstream, addressing concerns about the safety of some existing chemical sunscreen ingredients.

The FDA's approval of bemotrizinol may lead to the development of better sunscreens in the US, which could help reduce the incidence of skin cancer, the most common form of cancer. According to dermatologists, using broad-spectrum sunscreens that protect against both UVA and UVB rays is crucial for preventing premature aging, wrinkles, and skin cancer.

Despite the benefits of sunscreens, there has been a backlash against their use on social media, fueled by misinformation about their safety. Dr. Rogers says this trend is concerning, as skin cancer is a significant public health issue. The approval of bemotrizinol may help alleviate some of these concerns and promote the use of sunscreens as a crucial part of sun protection.

As the US sunscreen market evolves, consumers can expect to see new products containing bemotrizinol. While it may take some time for these products to become widely available, dermatologists are optimistic about the potential benefits of this new ingredient. With its broad-spectrum protection and photostability, bemotrizinol may become a game-changer in the fight against skin cancer.

In the meantime, consumers can continue to use existing sunscreens that provide broad-spectrum protection, while looking out for new products containing bemotrizinol. As always, it is essential to follow the instructions for use and reapply sunscreen every two hours to ensure adequate protection.

The FDA's approval of bemotrizinol is a significant step forward in the development of safer and more effective sunscreens. As research continues to uncover the benefits and risks of various sunscreen ingredients, consumers can rely on dermatologists and regulatory agencies to provide guidance on the best ways to protect their skin from the sun. With the arrival of bemotrizinol, the future of sun protection looks brighter than ever.